Floatz logo

Lipotecan

Portal Vein Tumor Thrombosis

Taiwan Liposome CompanySmall moleculePhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Portal Vein Tumor Thrombosis cohort.

Asset / SponsorPhaseRating
Ethiodized Oil
Zhongda Hospital
N/AD
Sorafenib
Zhongda Hospital
N/AD
Theprubicin
Zhongda Hospital
N/AD

Same molecule, other indications

Lipotecan is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
cancerDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →